Theraclion

Equities

ALTHE

FR0010120402

Advanced Medical Equipment & Technology

Real-time Euronext Paris Other stock markets 03:02:42 2024-04-25 am EDT			5-day change	1st Jan Change
0.362 ^EUR	0.00%		-2.16%	-6.70%

Mar. 27	Theraclion SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Theraclion Achieves an Important Milestone on the Road to the U.S. Market: First Patients Treated with Sonovein as Part of the Fda- Approved Pivotal Study	CI

Theraclion : AGM 2022 Présentation

June 30, 2022 at 11:53 am EDT

AGM

Présentation

Yann Duchesne

David Caumartin

David Auregan

Paris - 30 juin 2022

Déroulé de l'Assemblée Générale Mixte

Malakoff, le 30 juin 2022

Ouverture de l'assemblée par le Président
Constitution du bureau
- Président Yann Duchesne
- Scrutateurs David Auregan & David Caumartin
- Secrétaire David Auregan
Annonce du quorum AGO&AGE 9 428 770 voix soit 39,505% / Dépôts des documents sur le bureau
Présentation de l'activité au cours de l'exercice clos le 31 décembre
2021
Présentation des comptes de l'exercice clos le 31 décembre 2021
Présentation des rapports du commissaire aux comptes
Présentation par le Secrétaire des résolutions
Clôture de l'assemblée

28.06.2022

Management

Présentation de l'activité 2022

David Caumartin

Paris - Juin 2022

THERACLION'S LEADERSHIP TEAM

Yann Duchesne

Executive Chairman

Former Managing Partner of McKinsey
France
Senior Partner in private equity fund
Doughty Hanson
Group CEO of industrial and commercial conglomerate IBL Group
Chairman of pharmaceutical group
Medis
Founding shareholder of California- based biotechnology company Phylex

David Caumartin

Chief Executive Officer

CEO of Theraclion since 2014
14 years at GE Healthcare:

Sales

Marketing

Product Development

1. Computed Tomography and Radiology (8yr) o Global Mammography Activity Director (4yr)
VP Strategy in Mergers & Acquisitions at Alstom Thermal Power (2012-2014)
France Biotech Vice President since 2018

THERACLION

102, rue Etienne Dolet 92240 Malakoff

T +33 1 55 48 90 70

contact@theraclion.com

Finance:

david.auregan@theraclion.com

Marketing:

anja.kleber@theraclion.com

April 2022

HIGH INTENSITY FOCUSED ULTRASOUND (HIFU)

A Technology & Theraclion achievements

Technology

Spherical transducer

Concentrate at the focal

point

Variable depth

Adjustable focus

Theraclion's improvements

Focused acoustic wave

through the tissue with an effect at

the focal point

Localized tissue

heating (85°C)

Wide range of bioeffects

4 Principle of action

Non-thermalThermal ablation

Theraclion's R&D

Hyper-thermia Histotripsy

29 Biological effects

Image guided	Target to be treated	Cooling disposable
therapy
As small as 1x1.5mm or	device
Ultrasound vision
as large as 10x16mm	To control skin effects
co-registered on the target

including

Vascular occlusion		Vaso-constriction

Tissue destruction

June 22

Attachments

Original Link
Original Document
Permalink

Disclaimer

Theraclion SA published this content on 30 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 June 2022 15:52:07 UTC.

Latest news about Theraclion

Theraclion SA Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Theraclion Achieves an Important Milestone on the Road to the U.S. Market: First Patients Treated with Sonovein as Part of the Fda- Approved Pivotal Study	23-10-24	CI
Theraclion SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-11	CI
Inner Mongolia Furui Medical Science Co., Ltd. agreed to acquire an additional 27.78% stake in Theraclion Medical Equipment Co., Ltd. from Theraclion SA for ?1	23-09-27	CI
Theraclion: capital increase completed	23-06-23	CF
Theraclion SA announced that it has received â‚¬8.353961 million in funding from Furui Medical Science Company Luxembourg S.Ã r.l.	23-06-21	CI
Theraclion Names CEO	23-05-26	MT
Theraclion Appoints Martin Deterre as CEO	23-05-25	CI
Theraclion SA announced that it expects to receive €7 million in funding from Furui Medical Science Company Luxembourg S.à r.l.	23-05-24	CI
Theraclion SA announced that it expects to receive ?12.649999 million in funding from Furui Medical Science Company Luxembourg S.à r.l.	23-05-23	CI
Global markets live: HSBC, Logitech, Uber, IBM, BP...	23-05-02
Theraclion SA Auditor Raises 'Going Concern' Doubt	23-04-28	CI
Theraclion SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-28	CI
Theraclion: FDA approves pivotal study with Sonovein	23-04-18	CF
France's Theraclion Gets US FDA Nod for Clinical Trial of Varicose Veins Treatment	23-04-18	MT
Theraclion SA Announces US Food Drug Administration Approve Investigational Device Exemption Application to Initiate the Multi-Center Pivotal Study VEINRESET for the Treatment of Primary Insufficiency of Great Saphenous Veins with SONOVEIN	23-04-17	CI
Theraclion: boosted by positive results from US study	23-01-31	CF
Theraclion Announces Results of First US Trial	23-01-30	CI
Theraclion: partnership with the University of Virginia	22-12-22	CF
University of Virginia Cancer Center to Use Theraclion's HD Technology	22-12-21	CI
Theraclion SA Announces Last Patient of First Sonovein(R) US Study Has Been Treated	22-10-17	CI
Theraclion New Echotherapy for Varicose Veins Partnership with Parisian Region Hospital Wound Center Announced	22-09-29	CI
Theraclion SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-26	CI
Theraclion SA Announces Revenue Result for the First Half of 2022	22-07-27	CI
Theraclion SA Announces the Launch of SONOVEIN® HD	22-05-16	CI

Chart Theraclion

Duration

Period

More charts

Company Profile

Theraclion specializes in developping, manufacturing and marketing echotherapy equipment associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules.Net sales break down by activity as follows: - sale of equipment (61.8%); - sale of consumables (29%); - provision of after-sales services (9.2%). Export accounts for 99.7% of net sales.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-09-18 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
THERACLION	-6.70%	17.54M
THERMO FISHER SCIENTIFIC	+8.78%	220B
DANAHER CORPORATION	+8.24%	185B
INTUITIVE SURGICAL, INC.	+11.16%	133B
BOSTON SCIENTIFIC CORPORATION	+26.12%	107B
SIEMENS HEALTHINEERS AG	+0.04%	62.91B
EDWARDS LIFESCIENCES CORPORATION	+16.21%	53.34B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-1.63%	47.71B
AGILENT TECHNOLOGIES, INC.	-1.11%	40.29B
GE HEALTHCARE TECHNOLOGIES INC.	+12.16%	39.57B

Other Advanced Medical Equipment & Technology